Literature DB >> 27099436

Missing metastases as a model to challenge current therapeutic algorithms in colorectal liver metastases.

Valerio Lucidi1, Alain Hendlisz1, Jean-Luc Van Laethem1, Vincent Donckier1.   

Abstract

In oncosurgical approach to colorectal liver metastases, surgery remains considered as the only potentially curative option, while chemotherapy alone represents a strictly palliative treatment. However, missing metastases, defined as metastases disappearing after chemotherapy, represent a unique model to evaluate the curative potential of chemotherapy and to challenge current therapeutic algorithms. We reviewed recent series on missing colorectal liver metastases to evaluate incidence of this phenomenon, predictive factors and rates of cure defined by complete pathologic response in resected missing metastases and sustained clinical response when they were left unresected. According to the progresses in the efficacy of chemotherapeutic regimen, the incidence of missing liver metastases regularly increases these last years. Main predictive factors are small tumor size, low marker level, duration of chemotherapy, and use of intra-arterial chemotherapy. Initial series showed low rates of complete pathologic response in resected missing metastases and high recurrence rates when unresected. However, recent reports describe complete pathologic responses and sustained clinical responses reaching 50%, suggesting that chemotherapy could be curative in some cases. Accordingly, in case of missing colorectal liver metastases, the classical recommendation to resect initial tumor sites might have become partially obsolete. Furthermore, the curative effect of chemotherapy in selected cases could lead to a change of paradigm in patients with unresectable liver-only metastases, using intensive first-line chemotherapy to intentionally induce missing metastases, followed by adjuvant surgery on remnant chemoresistant tumors and close surveillance of initial sites that have been left unresected.

Entities:  

Keywords:  Chemotherapy; Colorectal; Liver; Metastases, Surgery; Missing

Mesh:

Year:  2016        PMID: 27099436      PMCID: PMC4823243          DOI: 10.3748/wjg.v22.i15.3937

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  54 in total

1.  Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy.

Authors:  Scott Kopetz; George J Chang; Michael J Overman; Cathy Eng; Daniel J Sargent; David W Larson; Axel Grothey; Jean-Nicolas Vauthey; David M Nagorney; Robert R McWilliams
Journal:  J Clin Oncol       Date:  2009-05-26       Impact factor: 44.544

2.  Complete response of colorectal liver metastases after chemotherapy: does it mean cure?

Authors:  Stéphane Benoist; Antoine Brouquet; Christophe Penna; Catherine Julié; Mostafa El Hajjam; Sophie Chagnon; Emmanuel Mitry; Philippe Rougier; Bernard Nordlinger
Journal:  J Clin Oncol       Date:  2006-08-20       Impact factor: 44.544

3.  Effect of subcentimeter nonpositive resection margin on hepatic recurrence in patients undergoing hepatectomy for colorectal liver metastases. Evidences from 663 liver resections.

Authors:  J Figueras; F Burdio; E Ramos; J Torras; L Llado; S Lopez-Ben; A Codina-Barreras; S Mojal
Journal:  Ann Oncol       Date:  2007-04-13       Impact factor: 32.976

4.  Predictors of a true complete response among disappearing liver metastases from colorectal cancer after chemotherapy.

Authors:  Rebecca C Auer; Rebekah R White; Nancy E Kemeny; Lawrence H Schwartz; Jinru Shia; Leslie H Blumgart; Ronald P Dematteo; Yuman Fong; William R Jarnagin; Michael I D'Angelica
Journal:  Cancer       Date:  2010-03-15       Impact factor: 6.860

5.  Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases?

Authors:  René Adam; Gerard Pascal; Denis Castaing; Daniel Azoulay; Valerie Delvart; Bernard Paule; Francis Levi; Henri Bismuth
Journal:  Ann Surg       Date:  2004-12       Impact factor: 12.969

6.  Performance of prognostic scores in predicting long-term outcome following resection of colorectal liver metastases.

Authors:  K J Roberts; A White; A Cockbain; J Hodson; E Hidalgo; G J Toogood; J P A Lodge
Journal:  Br J Surg       Date:  2014-06       Impact factor: 6.939

7.  Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of patterns of recurrence.

Authors:  K S Hughes; R Simon; S Songhorabodi; M A Adson; D M Ilstrup; J G Fortner; B J Maclean; J H Foster; J M Daly; D Fitzherbert
Journal:  Surgery       Date:  1986-08       Impact factor: 3.982

8.  Actual 10-year survival after resection of colorectal liver metastases defines cure.

Authors:  James S Tomlinson; William R Jarnagin; Ronald P DeMatteo; Yuman Fong; Peter Kornprat; Mithat Gonen; Nancy Kemeny; Murray F Brennan; Leslie H Blumgart; Michael D'Angelica
Journal:  J Clin Oncol       Date:  2007-10-10       Impact factor: 44.544

9.  'Close shave' in liver resection for colorectal liver metastases.

Authors:  J T Lordan; N D Karanjia
Journal:  Eur J Surg Oncol       Date:  2009-06-06       Impact factor: 4.424

10.  Radiological heterogeneity in response to chemotherapy is associated with poor survival in patients with colorectal liver metastases.

Authors:  C S van Kessel; M Samim; M Koopman; M A A J van den Bosch; I H M Borel Rinkes; C J A Punt; R van Hillegersberg
Journal:  Eur J Cancer       Date:  2013-05-18       Impact factor: 9.162

View more
  2 in total

1.  The Influence of Radiological "Disappearing Lesions" on the Efficacy and Prognosis of Patients with Colorectal Liver Metastases Undergoing Conversion Therapy.

Authors:  Zhi-Yang Song; Dong Yang; Yang Liu; Yong Cheng
Journal:  Gastroenterol Res Pract       Date:  2022-02-22       Impact factor: 2.260

2.  The dilemma of the disappeared colorectal liver metastasis: systematic review of reviews and evidence gap map.

Authors:  Ahmed Nassar; Sorin Cimpean; Amir Abdelhamid; Robert P Jones; Roger Wahba; Guido Fiorentini; Luca Aldrighetti; Catherine Teh; Ruslan Alikhanov; John Hammond; Michael Silva; Areeg Abdelmabod; Stephanie Truant; Alessandro Ferrero; Christian Sturesson; Irfan Ahmed; Mudassar Ghazanfar; Nobuyuki Takemura; Timothy M Pawlik; Mohamed Bekheit
Journal:  BJS Open       Date:  2022-05-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.